London, May 15, 2026, 09:08 BST
This week, Reckitt Benckiser Group plc spotlighted digital science and generative AI as key players in its growth strategy during an investor session. The company said these technologies now run through its Powerbrand lineup—Dettol, Lysol, Durex, Finish, Nurofen all included. Reckitt’s pitch: faster product development, and a better chance new products actually land with consumers.
This wasn’t a random move. Reckitt came up short on quarterly like-for-like net revenue forecasts last month — that measure excludes things like currency swings and portfolio shifts — and flagged that first-half margins could land roughly 200 basis points, or two percentage points, below where they stood a year ago. High oil prices and a mild cold and flu season took their toll.
Shares in Reckitt are still feeling the weight. AJ Bell had the stock pegged at 4,558p/4,559p early Friday—up just 0.29%. The year’s low sits at 4,518p, leaving the company with a market cap of roughly £29.2 billion.
Thursday’s “Focus On: Digital Science” event featured Chief R&D Officer Angela Naef, CFO Shannon Eisenhardt, Chief Information and Digitisation Officer Nigel Richardson, and Bastien Parizot, who leads AI enterprise. According to a regulatory filing, Reckitt did not plan to release any new material financial or trading updates during the presentation. Investegate
Reckitt describes digital science as a combination of simulation, predictive tools, and generative AI. Put simply, it’s data models running experiments on-screen before moving to pricier lab tests. Generative AI here means software that produces or interprets content from data patterns. “How quickly you can prove” an idea is key, according to Naef. Parizot added that the AI effort has to be “business-led, value-proofed” with “humans fully in the lead.”
The programme has slashed time spent on lower-value R&D tasks by as much as 70%, according to the company. Reckitt also noted a roughly 25% year-on-year bump in average innovation project size. The tools are now in use across all Powerbrands, spanning over 20 countries. More than 2,000 R&D and marketing employees have gone through training to use them, Reckitt said.
This goes beyond ramping up lab speed. Reckitt linked the new tools directly to its medium-term ambition: Core Reckitt is chasing 4% to 5% like-for-like net revenue growth, plus holding its fixed cost base under 19% of net revenue by end-2027.
The shift fits right into the wider pressure squeezing the consumer goods sector. Unilever plans “small doses” of price hikes to counter cost increases tied to the Iran war. Procter & Gamble, for its part, signaled it could take about a $1 billion after-tax profit hit in fiscal 2027 from steeper oil prices. Reuters
The risk is straightforward: even solid data might fail to counter sluggish demand, geopolitical headwinds, or climbing input costs. Reckitt posted first-quarter like-for-like revenue growth of just 1.3%, lagging the 2.9% consensus from its own poll, according to Reuters. JPMorgan’s Celine Pannuti flagged concerns in a client note, pointing to shaky outlooks for emerging markets in the second quarter—which puts the company’s full-year guidance in question.
Oil’s still in the spotlight. Brent crude picked up roughly 1.7% on Friday, landing at $107.49 a barrel. Prices climbed, Reuters noted, as traders sized up tensions near the Strait of Hormuz and the conflict involving Iran.
Reckitt hasn’t finished streamlining. After offloading its Essential Home business for $4.8 billion in December, the group is concentrating on its main health and hygiene lines. The company is also weighing what to do with Mead Johnson, its infant formula arm.
What investors are looking for now isn’t just credible tech—it’s evidence that bigger projects and quicker testing start making a difference in volumes and margins, and that seasonal stumbles become less frequent. So far, Reckitt has only quantified process tweaks, stopping short of offering a fresh outlook.
